Dengue virus serotype 3 capsid, envelope, and membrane proteins (None commonly used; individual proteins may be abbreviated as C, E, and M)

Dengue virus serotype 3 structural proteins are the three major proteins forming the viral particle: the capsid protein (C), which packages the viral RNA; the envelope protein (E), which mediates viral attachment and fusion with host cells; and the membrane protein (M), which assists in virion assembly and stability[4][3]. These proteins are encoded by the viral genome and synthesized as part of a polyprotein precursor that is processed during viral replication. The E protein is particularly significant as the principal target of neutralizing antibodies and is involved in the antigenic diversity underlying dengue virus’s capacity to evade immune responses. No licensed therapeutics target these proteins directly, but vaccines (including live-attenuated and recombinant forms) aim to induce immunity against them. Clinical safety concerns center on immune-mediated disease enhancement due to suboptimal antibody responses, especially to the E protein[4]. Dengue virus encodes a single polyprotein, which is post-translationally processed to yield three structural proteins (C, E, and M) and seven nonstructural proteins[4]. Capsid (C) protein forms the nucleocapsid and packages viral RNA, typically homodimerizing in the virion core[3]. Membrane (M) protein is initially synthesized as a precursor (prM) that is later cleaved during maturation to become the M protein, contributing to virion stability and infectivity[2]. Envelope (E) protein is the primary mediator of host-cell binding and fusion and is the major antigenic determinant for the host immune response and neutralizing antibodies; hence, it is a vaccine focus[2][4]. No licensed antivirals directly target these structural proteins, but monoclonal antibody therapies and vaccine candidates are designed based on E protein epitopes[4]. Serotype-specificity: While the molecular functions are conserved, antigenicity varies by serotype, which is critical for immunogenicity and disease enhancement risk. If greater specificity is required (e.g., structural details of a single protein or therapeutics targeting DENV-3), each protein can be further described individually.

Other names

Dengue virus type 3 structural proteinsDENV-3 C protein (Capsid)DENV-3 E protein (Envelope)DENV-3 M protein (Membrane)

Null (no small molecule drugs approved; monoclonal antibodies neutralize E protein functions, and vaccines elicit host immune responses against E and M proteins)